O	0	3	The	The	DT	B-NP
O	4	10	impact	impact	NN	I-NP
O	11	13	of	of	IN	B-PP
B-Multi-tissue_structure	14	22	tracheal	tracheal	JJ	B-NP
O	23	33	intubation	intubation	NN	I-NP
O	34	36	on	on	IN	B-PP
O	37	41	host	host	NN	B-NP
O	42	50	defenses	defense	NNS	I-NP
O	51	54	and	and	CC	I-NP
O	55	60	risks	risk	NNS	I-NP
O	61	64	for	for	IN	B-PP
O	65	75	nosocomial	nosocomial	JJ	B-NP
O	76	85	pneumonia	pneumonia	NN	I-NP
O	85	86	.	.	.	O

O	87	97	Nosocomial	Nosocomial	JJ	B-NP
O	98	107	pneumonia	pneumonia	NN	I-NP
O	108	115	remains	remain	VBZ	B-VP
O	116	117	a	a	DT	B-NP
O	118	124	common	common	JJ	I-NP
O	125	137	complication	complication	NN	I-NP
O	138	140	in	in	IN	B-PP
O	141	149	patients	patient	NNS	B-NP
O	150	157	treated	treat	VBN	B-VP
O	158	162	with	with	IN	B-PP
B-Immaterial_anatomical_entity	163	175	endotracheal	endotracheal	JJ	B-NP
O	176	186	intubation	intubation	NN	I-NP
O	187	190	and	and	CC	O
O	191	201	mechanical	mechanical	JJ	B-NP
O	202	213	ventilation	ventilation	NN	I-NP
O	214	217	and	and	CC	O
O	218	227	continues	continue	VBZ	B-VP
O	228	230	to	to	TO	I-VP
O	231	235	have	have	VB	I-VP
O	236	237	a	a	DT	B-NP
O	238	249	significant	significant	JJ	I-NP
O	250	256	impact	impact	NN	I-NP
O	257	259	on	on	IN	B-PP
O	260	263	the	the	DT	B-NP
O	264	273	mortality	mortality	NN	I-NP
O	274	278	rate	rate	NN	I-NP
O	279	281	of	of	IN	B-PP
O	282	287	these	these	DT	B-NP
O	288	296	patients	patient	NNS	I-NP
O	296	297	.	.	.	O

O	298	311	Epidemiologic	Epidemiologic	JJ	B-NP
O	312	319	studies	study	NNS	I-NP
O	320	324	have	have	VBP	B-VP
O	325	330	shown	show	VBN	I-VP
O	331	335	that	that	IN	B-SBAR
O	336	339	the	the	DT	B-NP
O	340	344	risk	risk	NN	I-NP
O	345	347	of	of	IN	B-PP
O	348	357	pneumonia	pneumonia	NN	B-NP
O	358	367	increases	increase	VBZ	B-VP
O	368	372	with	with	IN	B-PP
O	373	376	the	the	DT	B-NP
O	377	385	duration	duration	NN	I-NP
O	386	388	of	of	IN	B-PP
O	389	399	intubation	intubation	NN	B-NP
O	400	403	but	but	CC	O
O	404	408	that	that	IN	B-SBAR
O	409	412	the	the	DT	B-NP
O	413	419	period	period	NN	I-NP
O	420	422	of	of	IN	B-PP
O	423	430	highest	high	JJS	B-NP
O	431	435	risk	risk	NN	I-NP
O	436	438	is	be	VBZ	B-VP
O	439	442	the	the	DT	B-NP
O	443	448	first	first	JJ	I-NP
O	449	450	2	2	CD	I-NP
O	451	456	weeks	week	NNS	I-NP
O	457	459	of	of	IN	B-PP
O	460	467	therapy	therapy	NN	B-NP
O	467	468	.	.	.	O

O	469	473	Gram	Gram	NN	B-NP
O	473	474	-	-	HYPH	I-NP
O	474	482	negative	negative	JJ	I-NP
O	483	491	bacteria	bacteria	NNS	I-NP
O	492	499	account	account	VBP	B-VP
O	500	503	for	for	IN	B-PP
O	504	508	most	most	JJS	B-NP
O	509	519	nosocomial	nosocomial	JJ	I-NP
O	520	530	pneumonias	pneumonia	NNS	I-NP
O	531	533	in	in	IN	B-PP
O	534	543	intubated	intubated	JJ	B-NP
O	544	552	patients	patient	NNS	I-NP
O	552	553	,	,	,	O
O	554	557	but	but	CC	O
O	558	572	Staphylococcus	Staphylococcus	NNP	B-NP
O	573	579	aureus	aureus	NN	I-NP
O	580	583	may	may	MD	B-VP
O	584	588	also	also	RB	I-VP
O	589	593	play	play	VB	I-VP
O	594	595	a	a	DT	B-NP
O	596	600	role	role	NN	I-NP
O	601	603	in	in	IN	B-PP
O	604	608	what	what	WP	B-NP
O	609	612	may	may	MD	B-VP
O	613	615	be	be	VB	I-VP
O	616	617	a	a	DT	B-NP
O	618	631	polymicrobial	polymicrobial	JJ	I-NP
O	632	641	infection	infection	NN	I-NP
O	641	642	.	.	.	O

O	643	645	In	In	IN	B-PP
O	646	649	the	the	DT	O
O	650	654	most	most	RBS	B-ADVP
O	655	664	seriously	seriously	RB	I-ADVP
O	665	668	ill	ill	JJ	B-NP
O	669	680	individuals	individual	NNS	I-NP
O	680	681	,	,	,	O
O	682	685	and	and	CC	O
O	686	688	in	in	IN	B-PP
O	689	694	those	those	DT	B-NP
O	695	702	treated	treat	VBN	B-VP
O	703	707	with	with	IN	B-PP
O	708	712	long	long	JJ	B-NP
O	712	713	-	-	HYPH	I-NP
O	713	717	term	term	NN	I-NP
O	718	728	mechanical	mechanical	JJ	I-NP
O	729	740	ventilation	ventilation	NN	I-NP
O	740	741	,	,	,	O
O	742	753	Pseudomonas	Pseudomonas	NN	B-NP
O	754	764	aeruginosa	aeruginosa	NN	I-NP
O	765	767	is	be	VBZ	B-VP
O	768	769	a	a	DT	B-NP
O	770	776	common	common	JJ	I-NP
O	777	785	pathogen	pathogen	NN	I-NP
O	785	786	.	.	.	O

B-Immaterial_anatomical_entity	787	799	Endotracheal	Endotracheal	JJ	B-NP
O	800	810	intubation	intubation	NN	I-NP
O	811	814	and	and	CC	O
O	815	825	mechanical	mechanical	JJ	B-NP
O	826	837	ventilation	ventilation	NN	I-NP
O	838	848	predispose	predispose	NN	I-NP
O	849	851	to	to	TO	B-PP
O	852	861	pneumonia	pneumonia	NN	B-NP
O	862	865	for	for	IN	B-PP
O	866	867	a	a	DT	B-NP
O	868	875	variety	variety	NN	I-NP
O	876	878	of	of	IN	B-PP
O	879	886	reasons	reason	NNS	B-NP
O	887	888	(	(	(	O
O	888	891	see	see	VB	B-VP
O	892	895	Fig	Fig	NNP	B-NP
O	895	896	.	.	.	I-NP
O	897	898	1	1	CD	I-NP
O	898	899	)	)	)	O
O	899	900	.	.	.	O

O	901	904	The	The	DT	B-NP
B-Multi-tissue_structure	905	917	endotracheal	endotracheal	JJ	I-NP
I-Multi-tissue_structure	918	922	tube	tube	NN	I-NP
O	923	926	can	can	MD	B-VP
O	927	931	have	have	VB	I-VP
O	932	938	direct	direct	JJ	B-NP
O	939	946	effects	effect	NNS	I-NP
O	947	949	on	on	IN	B-PP
O	950	953	the	the	DT	B-NP
B-Multi-tissue_structure	954	960	airway	airway	NN	I-NP
O	961	965	that	that	WDT	B-NP
O	966	972	result	result	VBP	B-VP
O	973	975	in	in	IN	B-PP
O	976	977	a	a	DT	B-NP
O	978	987	reduction	reduction	NN	I-NP
O	988	990	in	in	IN	B-PP
O	991	996	local	local	JJ	B-NP
O	997	1001	host	host	NN	I-NP
O	1002	1010	defenses	defense	NNS	I-NP
O	1010	1011	.	.	.	O

O	1012	1016	Thus	Thus	RB	B-ADVP
O	1016	1017	,	,	,	O
B-Multi-tissue_structure	1018	1025	mucosal	mucosal	JJ	B-NP
O	1026	1032	injury	injury	NN	I-NP
O	1033	1036	can	can	MD	B-VP
O	1037	1043	reduce	reduce	VB	I-VP
B-Tissue	1044	1055	mucociliary	mucociliary	JJ	B-NP
O	1056	1064	function	function	NN	I-NP
O	1064	1065	,	,	,	O
O	1066	1071	while	while	IN	B-SBAR
O	1072	1077	upper	upper	JJ	B-NP
B-Multi-tissue_structure	1078	1084	airway	airway	NN	I-NP
O	1085	1093	defenses	defense	NNS	I-NP
O	1094	1097	are	be	VBP	B-VP
O	1098	1106	bypassed	bypass	VBN	I-VP
O	1107	1110	and	and	CC	O
O	1111	1114	the	the	DT	B-NP
O	1115	1128	effectiveness	effectiveness	NN	I-NP
O	1129	1131	of	of	IN	B-PP
O	1132	1137	cough	cough	NN	B-NP
O	1138	1140	is	be	VBZ	B-VP
O	1141	1148	reduced	reduce	VBN	I-VP
O	1148	1149	.	.	.	O

O	1150	1160	Indirectly	Indirectly	RB	B-ADVP
O	1160	1161	,	,	,	O
O	1162	1172	intubation	intubation	NN	B-NP
O	1173	1176	can	can	MD	B-VP
O	1177	1183	result	result	VB	I-VP
O	1184	1186	in	in	IN	B-PP
O	1187	1189	an	an	DT	B-NP
O	1190	1198	enhanced	enhance	VBN	I-NP
O	1199	1207	capacity	capacity	NN	I-NP
O	1208	1210	of	of	IN	B-PP
B-Cell	1211	1227	tracheobronchial	tracheobronchial	JJ	B-NP
I-Cell	1228	1233	cells	cell	NNS	I-NP
O	1234	1236	to	to	TO	B-VP
O	1237	1241	bind	bind	VB	I-VP
O	1242	1246	gram	gram	NN	B-NP
O	1246	1247	-	-	HYPH	B-NP
O	1247	1255	negative	negative	JJ	I-NP
O	1256	1264	bacteria	bacteria	NNS	I-NP
O	1264	1265	,	,	,	O
O	1266	1268	an	an	DT	B-NP
O	1269	1275	effect	effect	NN	I-NP
O	1276	1280	that	that	WDT	B-NP
O	1281	1287	favors	favor	VBZ	B-VP
B-Multi-tissue_structure	1288	1294	airway	airway	NN	B-NP
O	1295	1307	colonization	colonization	NN	I-NP
O	1308	1311	and	and	CC	I-NP
O	1312	1321	pneumonia	pneumonia	NN	I-NP
O	1321	1322	.	.	.	O

O	1323	1326	The	The	DT	B-NP
O	1327	1333	injury	injury	NN	I-NP
O	1334	1336	to	to	TO	B-PP
O	1337	1340	the	the	DT	B-NP
B-Multi-tissue_structure	1341	1347	airway	airway	NN	I-NP
O	1348	1351	can	can	MD	B-VP
O	1352	1358	create	create	VB	I-VP
O	1359	1366	binding	bind	VBG	B-NP
O	1367	1372	sites	site	NNS	I-NP
O	1373	1376	for	for	IN	B-PP
O	1377	1385	bacteria	bacteria	NNS	B-NP
O	1386	1388	in	in	IN	B-PP
O	1389	1392	the	the	DT	B-NP
B-Cellular_component	1393	1401	basement	basement	NN	I-NP
I-Cellular_component	1402	1410	membrane	membrane	NN	I-NP
O	1411	1413	of	of	IN	B-PP
O	1414	1417	the	the	DT	B-NP
B-Multi-tissue_structure	1418	1427	bronchial	bronchial	JJ	I-NP
I-Multi-tissue_structure	1428	1432	tree	tree	NN	I-NP
O	1433	1436	and	and	CC	O
O	1437	1440	the	the	DT	B-NP
O	1441	1452	stimulation	stimulation	NN	I-NP
O	1453	1455	of	of	IN	B-PP
O	1456	1459	the	the	DT	B-NP
O	1460	1469	secretion	secretion	NN	I-NP
O	1470	1472	of	of	IN	B-PP
B-Organism_substance	1473	1478	mucus	mucus	NN	B-NP
O	1478	1479	,	,	,	O
O	1480	1485	which	which	WDT	B-NP
O	1486	1490	then	then	RB	B-NP
O	1491	1500	stagnates	stagnate	NNS	I-NP
O	1501	1504	and	and	CC	O
O	1505	1508	can	can	MD	B-VP
O	1509	1515	create	create	VB	I-VP
O	1516	1525	potential	potential	JJ	B-NP
O	1526	1531	sites	site	NNS	I-NP
O	1532	1535	for	for	IN	B-PP
O	1536	1545	bacterial	bacterial	JJ	B-NP
O	1546	1555	adherence	adherence	NN	I-NP
O	1555	1556	.	.	.	O

O	1557	1560	The	The	DT	B-NP
B-Multi-tissue_structure	1561	1573	endotracheal	endotracheal	JJ	I-NP
I-Multi-tissue_structure	1574	1578	tube	tube	NN	I-NP
O	1579	1583	also	also	RB	B-ADVP
O	1584	1592	enhances	enhance	VBZ	B-VP
O	1593	1602	bacterial	bacterial	JJ	B-NP
O	1603	1608	entry	entry	NN	I-NP
O	1609	1611	to	to	TO	B-PP
O	1612	1615	the	the	DT	B-NP
B-Organ	1616	1620	lung	lung	NN	I-NP
O	1621	1623	by	by	IN	B-PP
O	1624	1631	serving	serve	VBG	B-VP
O	1632	1634	as	as	IN	B-PP
O	1635	1636	a	a	DT	B-NP
O	1637	1646	reservoir	reservoir	NN	I-NP
O	1647	1650	for	for	IN	B-PP
O	1651	1659	bacteria	bacteria	NNS	B-NP
O	1660	1662	to	to	TO	B-VP
O	1663	1669	remain	remain	VB	I-VP
O	1670	1681	sequestered	sequestered	JJ	B-ADJP
O	1681	1682	,	,	,	O
O	1683	1687	safe	safe	JJ	B-ADJP
O	1688	1692	from	from	IN	B-PP
O	1693	1697	host	host	NN	B-NP
O	1698	1706	defenses	defense	NNS	I-NP
O	1706	1707	.	.	.	O

B-Anatomical_system	1708	1719	Respiratory	Respiratory	JJ	B-NP
O	1720	1727	therapy	therapy	NN	I-NP
O	1728	1735	devices	device	NNS	I-NP
O	1736	1739	can	can	MD	B-VP
O	1740	1745	allow	allow	VB	I-VP
O	1746	1754	bacteria	bacteria	NNS	B-NP
O	1755	1757	to	to	TO	B-VP
O	1758	1769	proliferate	proliferate	VB	I-VP
O	1770	1773	and	and	CC	O
O	1774	1777	can	can	MD	B-VP
O	1778	1782	then	then	RB	I-VP
O	1783	1792	introduce	introduce	VB	I-VP
O	1793	1797	them	them	PRP	B-NP
O	1798	1802	into	into	IN	B-PP
O	1803	1806	the	the	DT	B-NP
O	1807	1814	patient	patient	NN	I-NP
O	1815	1817	if	if	IN	B-SBAR
O	1818	1821	not	not	RB	O
O	1822	1829	handled	handle	VBN	B-VP
O	1830	1838	properly	properly	RB	B-ADVP
O	1838	1839	.	.	.	O

O	1840	1847	Finally	Finally	RB	B-ADVP
O	1847	1848	,	,	,	O
O	1849	1857	patients	patient	NNS	B-NP
O	1858	1861	who	who	WP	B-NP
O	1862	1865	are	be	VBP	B-VP
O	1866	1869	ill	ill	RB	B-ADJP
O	1870	1876	enough	enough	RB	I-ADJP
O	1877	1879	to	to	TO	B-VP
O	1880	1887	require	require	VB	I-VP
O	1888	1898	intubation	intubation	NN	B-NP
O	1899	1903	also	also	RB	B-ADVP
O	1904	1908	have	have	VBP	B-VP
O	1909	1916	disease	disease	NN	B-NP
O	1916	1917	-	-	HYPH	B-NP
O	1917	1927	associated	associate	VBN	I-NP
O	1928	1939	impairments	impairment	NNS	I-NP
O	1940	1942	in	in	IN	B-PP
O	1943	1951	systemic	systemic	JJ	B-NP
O	1952	1956	host	host	NN	I-NP
O	1957	1964	defense	defense	NN	I-NP
O	1964	1965	,	,	,	O
O	1966	1971	which	which	WDT	B-NP
O	1972	1975	add	add	VBP	B-VP
O	1976	1978	to	to	TO	B-PP
O	1979	1982	the	the	DT	B-NP
O	1983	1994	impairments	impairment	NNS	I-NP
O	1995	2001	caused	cause	VBN	B-VP
O	2002	2004	by	by	IN	B-PP
O	2005	2008	the	the	DT	B-NP
O	2009	2012	use	use	NN	I-NP
O	2013	2015	of	of	IN	B-PP
O	2016	2018	an	an	DT	B-NP
O	2019	2029	artificial	artificial	JJ	I-NP
B-Multi-tissue_structure	2030	2036	airway	airway	NN	I-NP
O	2036	2037	.	.	.	O

O	2038	2041	The	The	DT	B-NP
O	2042	2046	host	host	NN	I-NP
O	2047	2054	defense	defense	NN	I-NP
O	2055	2066	impairments	impairment	NNS	I-NP
O	2067	2071	that	that	WDT	B-NP
O	2072	2077	occur	occur	VBP	B-VP
O	2078	2080	in	in	IN	B-PP
O	2081	2093	mechanically	mechanically	RB	B-NP
O	2094	2104	ventilated	ventilate	VBN	I-NP
O	2105	2113	patients	patient	NNS	I-NP
O	2114	2117	can	can	MD	B-VP
O	2118	2122	lead	lead	VB	I-VP
O	2123	2125	to	to	TO	B-PP
B-Organism_subdivision	2126	2137	respiratory	respiratory	JJ	B-NP
I-Organism_subdivision	2138	2143	tract	tract	NN	I-NP
O	2144	2153	infection	infection	NN	I-NP
O	2154	2156	in	in	IN	B-PP
O	2157	2160	the	the	DT	B-NP
O	2161	2165	form	form	NN	I-NP
O	2166	2168	of	of	IN	B-PP
O	2169	2175	either	either	CC	B-NP
O	2176	2183	febrile	febrile	JJ	I-NP
O	2184	2201	tracheobronchitis	tracheobronchitis	NN	I-NP
O	2202	2204	or	or	CC	I-NP
O	2205	2214	pneumonia	pneumonia	NN	I-NP
O	2214	2215	.	.	.	O

O	2216	2219	The	The	DT	B-NP
O	2220	2229	diagnosis	diagnosis	NN	I-NP
O	2230	2232	of	of	IN	B-PP
O	2233	2242	pneumonia	pneumonia	NN	B-NP
O	2243	2245	in	in	IN	B-PP
O	2246	2255	intubated	intubated	JJ	B-NP
O	2256	2264	patients	patient	NNS	I-NP
O	2265	2267	is	be	VBZ	B-VP
O	2268	2277	difficult	difficult	JJ	B-ADJP
O	2278	2281	and	and	CC	I-ADJP
O	2282	2295	controversial	controversial	JJ	I-ADJP
O	2295	2296	.	.	.	O

O	2297	2299	It	It	PRP	B-NP
O	2300	2303	can	can	MD	B-VP
O	2304	2306	be	be	VB	I-VP
O	2307	2311	made	make	VBN	I-VP
O	2312	2314	by	by	IN	B-PP
O	2315	2321	either	either	CC	O
O	2322	2330	clinical	clinical	JJ	B-NP
O	2331	2339	criteria	criterion	NNS	I-NP
O	2340	2342	or	or	CC	O
O	2343	2356	microbiologic	microbiologic	JJ	B-NP
O	2357	2365	criteria	criterion	NNS	I-NP
O	2365	2366	,	,	,	O
O	2367	2370	the	the	DT	B-NP
O	2371	2377	latter	latter	JJ	I-NP
O	2378	2380	by	by	IN	B-PP
O	2381	2386	using	use	VBG	B-VP
O	2387	2388	a	a	DT	B-NP
O	2389	2406	bronchoscopically	bronchoscopically	RB	I-NP
O	2407	2415	directed	direct	VBN	I-NP
O	2416	2425	protected	protected	JJ	I-NP
O	2426	2434	specimen	specimen	NN	I-NP
O	2435	2440	brush	brush	NN	I-NP
O	2440	2441	.	.	.	O

O	2442	2449	Therapy	Therapy	NN	B-NP
O	2450	2452	of	of	IN	B-PP
O	2453	2462	pneumonia	pneumonia	NN	B-NP
O	2463	2465	in	in	IN	B-PP
O	2466	2478	mechanically	mechanically	RB	B-NP
O	2479	2489	ventilated	ventilate	VBN	I-NP
O	2490	2498	patients	patient	NNS	I-NP
O	2499	2501	is	be	VBZ	B-VP
O	2502	2505	not	not	RB	O
O	2506	2512	always	always	RB	B-ADVP
O	2513	2523	successful	successful	JJ	B-ADJP
O	2523	2524	,	,	,	O
O	2525	2528	and	and	CC	O
O	2529	2537	systemic	systemic	JJ	B-NP
O	2538	2549	antibiotics	antibiotic	NNS	I-NP
O	2550	2553	may	may	MD	B-VP
O	2554	2558	need	need	VB	I-VP
O	2559	2561	to	to	TO	I-VP
O	2562	2564	be	be	VB	I-VP
O	2565	2577	supplemented	supplement	VBN	I-VP
O	2578	2580	by	by	IN	B-PP
O	2581	2588	topical	topical	JJ	B-NP
O	2589	2603	antimicrobials	antimicrobial	NNS	I-NP
O	2603	2604	.	.	.	O

O	2605	2607	No	No	DT	B-NP
O	2608	2615	clearly	clearly	RB	I-NP
O	2616	2625	effective	effective	JJ	I-NP
O	2626	2638	prophylactic	prophylactic	JJ	I-NP
O	2639	2647	strategy	strategy	NN	I-NP
O	2648	2657	currently	currently	RB	B-ADVP
O	2658	2664	exists	exist	VBZ	B-VP
O	2664	2665	,	,	,	O
O	2666	2669	but	but	CC	O
O	2670	2673	our	our	PRP$	B-NP
O	2674	2687	understanding	understanding	NN	I-NP
O	2688	2690	of	of	IN	B-PP
O	2691	2700	pneumonia	pneumonia	NN	B-NP
O	2701	2713	pathogenesis	pathogenesis	NN	I-NP
O	2714	2717	has	have	VBZ	B-VP
O	2718	2721	led	lead	VBN	I-VP
O	2722	2724	to	to	TO	B-PP
O	2725	2729	some	some	DT	B-NP
O	2730	2739	promising	promising	JJ	I-NP
O	2740	2750	directions	direction	NNS	I-NP
O	2750	2751	.	.	.	O

O	2752	2754	As	As	IN	B-SBAR
O	2755	2759	more	more	JJR	B-NP
O	2760	2764	data	datum	NNS	I-NP
O	2765	2768	are	be	VBP	B-VP
O	2769	2778	collected	collect	VBN	I-VP
O	2778	2779	,	,	,	O
O	2780	2787	inhaled	inhale	VBN	B-NP
O	2788	2799	antibiotics	antibiotic	NNS	I-NP
O	2799	2800	,	,	,	O
O	2801	2810	selective	selective	JJ	B-NP
O	2811	2820	digestive	digestive	JJ	I-NP
O	2821	2836	decontamination	decontamination	NN	I-NP
O	2836	2837	,	,	,	O
O	2838	2841	and	and	CC	O
O	2842	2853	enhancement	enhancement	NN	B-NP
O	2854	2856	of	of	IN	B-PP
O	2857	2861	host	host	NN	B-NP
O	2862	2870	defenses	defense	NNS	I-NP
O	2871	2873	by	by	IN	B-PP
O	2874	2883	cytokines	cytokine	NNS	B-NP
O	2884	2887	and	and	CC	O
O	2888	2891	pre	pre	AFX	O
O	2891	2892	-	-	HYPH	O
O	2892	2898	formed	form	VBN	B-NP
O	2899	2909	antibodies	antibody	NNS	I-NP
O	2910	2913	may	may	MD	B-VP
O	2914	2920	emerge	emerge	VB	I-VP
O	2921	2923	as	as	IN	B-PP
O	2924	2930	useful	useful	JJ	B-NP
O	2931	2941	approaches	approach	NNS	I-NP
O	2941	2942	.	.	.	O

